Search Results
Bispecific T-cell engaging therapy for adult ALL
Updates on bispecific T cell engagers (BiTEs) for the treatment of acute lymphoblastic leukaemia
Bispecific antibodies in B-ALL; blinatumomab
T Cell Engager Antibodies – focus on Hematological Malignancies | Presented by Dr. John Kuruvilla
Bispecific Gamma-Delta T Cell Engagers for the Treatment of Cancer
Trials of BiTEs for the treatment of acute leukemias
Innovations from the therapeutics antibody space: obligate bispecific antibodies & T cell engagers
Relapsed/Refractory B-cell Lymphomas in the CAR-T Era: Improving Outcomes in a Population at Need
Blinatumomab has promising effect on hard-to-treat, rare acute lymphoblastic leukaemia subtype
Update on CAR T-Cell Therapy | Lymphoma Research Foundation Webinars
Antibody Therapy in ALL: How and Why to Integrate Antibody-Based Treatment Into Patient Management
Transferring lessons learnt from treating ALL to AML
